drugset
drugset / Trial / NCT05983783

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

NCT05983783 ↗

Phase 3 Recruiting 200 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.

Timeline

Start
2023-08-01
Primary completion
2025-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — —
Comparator Rezvilutamide Small molecule 240 mg Oral

Indications

metastatic prostate carcinoma